This week in healthcare and pharmaceuticals, several important updates were announced. President Trump has selected a new candidate for the head of the FDA, which could bring changes to how drugs and medical products are regulated in the U.S. Meanwhile, rare diseases took center stage, with new treatments and research developments gaining attention.
Here’s a closer look at some of the key stories:
**New Funding for Schizophrenia Research:** Kynexis, a biopharmaceutical company, has raised €97 million ($113 million) to support the development of a new drug, KYN-5356. This drug is being tested to help improve thinking and memory problems in people with schizophrenia. The funds will help complete a U.S.-based study and prepare for larger trials. The company is working with partners like Novartis and Forbion to advance this research.
**Improving Sterile Drug Manufacturing in Europe:** New regulations in Europe are changing how sterile drugs are made. These changes focus on reducing risks of contamination and ensuring safer products. Experts at Thermo Fisher Scientific, like Ian Hudson, explain that companies need to adopt a continuous approach to quality control rather than treating it as a one-time task.
**Potential New FDA Commissioner:** President Trump is expected to nominate Heidi Overton as the next FDA commissioner. This appointment could bring new directions to the FDA after a period of frequent leadership changes, which may impact how drugs and medical devices are approved.
**Breakthroughs in Biotech Funding and Treatments:** Several companies secured major funding this week:
– **Khartis Therapeutics** raised $95 million to develop a new treatment for thyroid eye disease, an autoimmune condition affecting the eyes. Their lead drug is designed to block a specific protein involved in the disease.
– **Remepy** closed a $36 million funding round to advance a potential new treatment for Parkinson’s disease. Their drug, Hybridopa, is in late-stage testing and could begin global trials by the end of 2026.
**Crackdown on Fake Weight Loss Drugs:** Eli Lilly, the maker of retatrutide (an investigational weight loss drug), is taking action against illegal sellers of their medication. Many patients are turning to unverified sources, risking their safety. Lilly is filing lawsuits and reporting these sellers to authorities to protect patients.
These updates reflect ongoing progress in medicine, research, and drug safety. If you’d like to learn more about any of these stories, check out the provided links for detailed information.